BRISTOL-MYERS SQUIBB COMPANY vs Merck & Co., Inc., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BMY and MRK diverge most: on ev/ebitda, BMY reads 47.4 and MRK reads 629.4; on altman z (solvency), BMY reads 2.25 and MRK reads 7.31. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | BMY | MRK |
|---|---|---|
| Price | $65.30 | $130.21 |
| Market cap | $133.7B | $321.9B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | +11.4% |
| P/E | 14.3 | 36.7 |
| P/B | 5.99 | 7.01 |
| P/S | 2.72 | 4.89 |
| EV/EBITDA | 47.4 | 629.4 |
| Revenue growth | +3.1% | +2.9% |
| Net margin | 18.9% | 13.6% |
| Return on equity | 41.6% | 19.4% |
| Return on assets | 10.6% | 6.9% |
| FCF yield | 8.6% | 4.4% |
| Dividend yield | 3.8% | 2.5% |
| Debt / equity | 1.97 | 1.07 |
| Current ratio | 1.53 | 1.30 |
| Altman Z (solvency) | 2.25 | 7.31 |
| Piotroski F (quality) | 8 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.